Biologics beyond Anti-TNF Agents for Ulcerative Colitis — Efficacy, Safety, and Cost?
Author:
- 26 September 2019
- journal article
- editorial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 381 (13) , 1279-1281
Abstract
Ulcerative colitis typically manifests in young adults in their 20s and 30s and can progress from mild asymptomatic rectal inflammation to debilitating extensive colitis resulting in frequent bloody stools, systemic symptoms, and colorectal cancer.1 Approximately one third of patients with distal ulcerative colitis at the time of diagnosis will have more extensive colitis by 10 years,2 and 10 to 15% of patients with ulcerative colitis will ultimately require a colectomy.3-5 Biologic agents are recommended for patients with moderate-to-severe ulcerative colitis who have not had a response to conventional therapies such as aminosalicylates, corticosteroids, or immunomodulators or who cannot receive such . . .Keywords
This publication has 13 references indexed in Scilit:
- Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic ReviewClinical Gastroenterology and Hepatology, 2018
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2017
- Systematic review with meta‐analysis: proximal disease extension in limited ulcerative colitisAlimentary Pharmacology & Therapeutics, 2017
- Ulcerative colitisThe Lancet, 2017
- Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current ManagementJournal of Crohn's and Colitis, 2017
- Ustekinumab as Induction and Maintenance Therapy for Crohn’s DiseaseNew England Journal of Medicine, 2016
- Systematic review: outcomes and post‐operative complications following colectomy for ulcerative colitisAlimentary Pharmacology & Therapeutics, 2016
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2013
- Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN studyGut, 2012
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2005